Verhoeven Bart A N, Moll Frans L, Koekkoek Johan A F, van der Wal Allard C, de Kleijn Dominique P V, de Vries Jean Paul P M, Verheijen Jan H, Velema Evelyn, Busser Els, Schoneveld Arjan, Virmani Renu, Pasterkamp Gerard
Department of Vascular Surgery, University Medical Centre Utrecht, Utrecht, The Netherlands.
Stroke. 2006 Aug;37(8):2054-60. doi: 10.1161/01.STR.0000231685.82795.e5. Epub 2006 Jun 29.
Anti-inflammatory qualities are held partially responsible for the reduction of cardiovascular events after statin treatment. We examined the phenotype of carotid atherosclerotic plaques harvested during carotid endarterectomy in relation to the previous use of different statins prescribed in clinical practice.
Three hundred and seventy-eight patients were included. Atherosclerotic plaques were harvested, immunohistochemically stained and semiquantitively examined for the presence of macrophages (CD68), smooth muscle cells, collagen and fat. Adjacent atherosclerotic plaques were used to study protease activity and interleukin levels. Patients' demographics were recorded and blood samples were stored.
Serum cholesterol, low-density lipoprotein, apolipoprotein B, and C-reactive protein levels were lower in patients treated with statins compared with patients without statin treatment. Atheromatous plaques were less prevalent in patients receiving statins compared with patients without statin therapy (29% versus 42%, P=0.04). An increase of CD68 positive cells was observed in patients receiving statins compared with nonstatin treatment (P=0.05). This effect was specifically related to atorvastatin treatment. In patients treated with atorvastatin, the increased amount of CD68 positive cells were not associated with increased protease activity. In contrast, a dose-dependent decrease in protease activity was shown in the atorvastatin group. Interleukin 6 expression was lower in plaques obtained from patients treated with statins (P=0.04).
Statin use may exert pleiotropic effects on plaque phenotype. However, not the presence of macrophages but activation with subsequent protease and cytokine release may be attenuated by statin use.
抗炎特性部分解释了他汀类药物治疗后心血管事件减少的原因。我们研究了在颈动脉内膜切除术中获取的颈动脉粥样硬化斑块的表型,这些斑块与临床实践中先前使用的不同他汀类药物有关。
纳入378例患者。获取动脉粥样硬化斑块,进行免疫组织化学染色,并对巨噬细胞(CD68)、平滑肌细胞、胶原蛋白和脂肪的存在进行半定量检查。使用相邻的动脉粥样硬化斑块研究蛋白酶活性和白细胞介素水平。记录患者的人口统计学数据并储存血样。
与未接受他汀类药物治疗的患者相比,接受他汀类药物治疗的患者血清胆固醇、低密度脂蛋白、载脂蛋白B和C反应蛋白水平较低。与未接受他汀类药物治疗的患者相比,接受他汀类药物治疗的患者动脉粥样斑块的患病率较低(29%对42%,P=0.04)。与未接受他汀类药物治疗的患者相比,接受他汀类药物治疗的患者中观察到CD68阳性细胞增加(P=0.05)。这种效应与阿托伐他汀治疗特别相关。在接受阿托伐他汀治疗的患者中,CD68阳性细胞数量的增加与蛋白酶活性增加无关。相反,阿托伐他汀组显示蛋白酶活性呈剂量依赖性降低。他汀类药物治疗患者的斑块中白细胞介素6表达较低(P=0.04)。
使用他汀类药物可能对斑块表型产生多效性作用。然而,他汀类药物使用可能减弱的不是巨噬细胞的存在,而是随后蛋白酶和细胞因子释放的激活。